US biotech firm Juno Therapeutics (Nasdaq: JUNO) has appointed Sunil Agarwal as president of research and development.
With Dr Agarwal’s appointment, Juno will bring R&D under one leader responsible for the execution of Juno’s drug development pipeline, integration of translational insights into ongoing programs, and the prioritization of research and development initiatives. Prior to joining Juno, Dr Agarwal’s last industry role was chief medical officer, executive vice president at Ultragenyx.
Back in January, Juno poached former senior VP and head of global clinical operations and industry collaborations at a US subsidiary of Swiss pharma giant Roche to take the post of executive VP and head of development operations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze